Leqembi (lecanemab®)

Evicore finds Leqembi (lecanemab) not recommended for approval/coverage because clinical efficacy is insufficient and safety concerns were demonstrated, effectively excluding it. If requested, use would be limited to patients who meet the FDA‑approved indication and trial population (mild cognitive impairment or mild dementia) and applicable coverage/safety criteria, with documentation of disease stage required (no other specific tests listed).

"Leqembi is indicated for the treatment of Alzheimer's disease."

Sign up to see full coverage criteria, indications, and limitations.